Protection by ipratropium bromide and metaproterenol against methacholine and histamine bronchoconstriction

N. NAIR, R. G. TOWNLEY, G. WATT, S. SCHLANGER, A. K. BEWTRA, L. H. STEKOLL

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To establish relative protection against methacholine and histamine, 40 μg of ipratropium bromide, an anticholinergic compound, 1.3 mg of metaproterenol or placebo aerosols were administered by metered-dose inhaler prior to inhalation challenge with methacholine or histamine in nine asthmatic subjects. Double-blind, randomized challenges were performed. Subjects required a mean methacholine dose of 1.72 ± 0.73 and 2.46 ± 0.72 (Ln inhalation units), and mean histamine dose of 2.16 ± 0.65 and 2.68 ± 0.49, to cause a drop of 20% and 35% respectively in the FEV1 following the placebo. In the methacholine challenges, both ipratropium bromide and metaproterenol had significant protection as compared to placebo (P <0.001). There was no statistical difference in the degree of protection against methacholine between ipratropium bromide and metaproterenol. In histamine challenges, metaproterenol had significant protection as compared to the placebo, while ipratropium bromide did not protect against histamine.

Original languageEnglish
Pages (from-to)11-19
Number of pages9
JournalClinical Allergy
Volume14
Issue number1
DOIs
StatePublished - 1984

Fingerprint

Metaproterenol
Ipratropium
Bronchoconstriction
Methacholine Chloride
Histamine
Placebos
Inhalation
Metered Dose Inhalers
Cholinergic Antagonists
Aerosols

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Protection by ipratropium bromide and metaproterenol against methacholine and histamine bronchoconstriction. / NAIR, N.; TOWNLEY, R. G.; WATT, G.; SCHLANGER, S.; BEWTRA, A. K.; STEKOLL, L. H.

In: Clinical Allergy, Vol. 14, No. 1, 1984, p. 11-19.

Research output: Contribution to journalArticle

NAIR, N. ; TOWNLEY, R. G. ; WATT, G. ; SCHLANGER, S. ; BEWTRA, A. K. ; STEKOLL, L. H. / Protection by ipratropium bromide and metaproterenol against methacholine and histamine bronchoconstriction. In: Clinical Allergy. 1984 ; Vol. 14, No. 1. pp. 11-19.
@article{64f113867bd649d2bcb24cbfe7fc4f4b,
title = "Protection by ipratropium bromide and metaproterenol against methacholine and histamine bronchoconstriction",
abstract = "To establish relative protection against methacholine and histamine, 40 μg of ipratropium bromide, an anticholinergic compound, 1.3 mg of metaproterenol or placebo aerosols were administered by metered-dose inhaler prior to inhalation challenge with methacholine or histamine in nine asthmatic subjects. Double-blind, randomized challenges were performed. Subjects required a mean methacholine dose of 1.72 ± 0.73 and 2.46 ± 0.72 (Ln inhalation units), and mean histamine dose of 2.16 ± 0.65 and 2.68 ± 0.49, to cause a drop of 20{\%} and 35{\%} respectively in the FEV1 following the placebo. In the methacholine challenges, both ipratropium bromide and metaproterenol had significant protection as compared to placebo (P <0.001). There was no statistical difference in the degree of protection against methacholine between ipratropium bromide and metaproterenol. In histamine challenges, metaproterenol had significant protection as compared to the placebo, while ipratropium bromide did not protect against histamine.",
author = "N. NAIR and TOWNLEY, {R. G.} and G. WATT and S. SCHLANGER and BEWTRA, {A. K.} and STEKOLL, {L. H.}",
year = "1984",
doi = "10.1111/j.1365-2222.1984.tb02184.x",
language = "English",
volume = "14",
pages = "11--19",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Protection by ipratropium bromide and metaproterenol against methacholine and histamine bronchoconstriction

AU - NAIR, N.

AU - TOWNLEY, R. G.

AU - WATT, G.

AU - SCHLANGER, S.

AU - BEWTRA, A. K.

AU - STEKOLL, L. H.

PY - 1984

Y1 - 1984

N2 - To establish relative protection against methacholine and histamine, 40 μg of ipratropium bromide, an anticholinergic compound, 1.3 mg of metaproterenol or placebo aerosols were administered by metered-dose inhaler prior to inhalation challenge with methacholine or histamine in nine asthmatic subjects. Double-blind, randomized challenges were performed. Subjects required a mean methacholine dose of 1.72 ± 0.73 and 2.46 ± 0.72 (Ln inhalation units), and mean histamine dose of 2.16 ± 0.65 and 2.68 ± 0.49, to cause a drop of 20% and 35% respectively in the FEV1 following the placebo. In the methacholine challenges, both ipratropium bromide and metaproterenol had significant protection as compared to placebo (P <0.001). There was no statistical difference in the degree of protection against methacholine between ipratropium bromide and metaproterenol. In histamine challenges, metaproterenol had significant protection as compared to the placebo, while ipratropium bromide did not protect against histamine.

AB - To establish relative protection against methacholine and histamine, 40 μg of ipratropium bromide, an anticholinergic compound, 1.3 mg of metaproterenol or placebo aerosols were administered by metered-dose inhaler prior to inhalation challenge with methacholine or histamine in nine asthmatic subjects. Double-blind, randomized challenges were performed. Subjects required a mean methacholine dose of 1.72 ± 0.73 and 2.46 ± 0.72 (Ln inhalation units), and mean histamine dose of 2.16 ± 0.65 and 2.68 ± 0.49, to cause a drop of 20% and 35% respectively in the FEV1 following the placebo. In the methacholine challenges, both ipratropium bromide and metaproterenol had significant protection as compared to placebo (P <0.001). There was no statistical difference in the degree of protection against methacholine between ipratropium bromide and metaproterenol. In histamine challenges, metaproterenol had significant protection as compared to the placebo, while ipratropium bromide did not protect against histamine.

UR - http://www.scopus.com/inward/record.url?scp=0021347194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021347194&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2222.1984.tb02184.x

DO - 10.1111/j.1365-2222.1984.tb02184.x

M3 - Article

C2 - 6230176

AN - SCOPUS:0021347194

VL - 14

SP - 11

EP - 19

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

SN - 0954-7894

IS - 1

ER -